It could also efficaciously pass through the BBB and exert antitumor effects in glioma and AML animal models with IDH R132 mutations.484 Two open-label phase I trials of BAY-1436032 are ongoing to evaluate its PDs, safety, tolerability, and preliminary efficacy in patients with AML (NCT03127735) and solid tumors (NCT02746081), but the initial results have not been announced. The gene discussed is IDH1; the disease is central nervous system cancer.